Dexamethasone is used to treat many inflammatory and autoimmune conditions, e.g., rheumatoid arthritis. It is also given to cancer patients undergoing chemotherapy, to counteract certain side-effects of their antitumor treatment. Dexamethasone can augment the antiemetic effect of 5-HT3 receptor antagonists like ondansetron. It is also given in small amounts (usually 5-6 tablets) before and/or after some forms of dental surgery, such as the extraction of the wisdom teeth, an operation which often leaves the patient with puffy, swollen cheeks. conditions, e.g., . It is also given to patients undergoing , to counteract certain of their antitumor treatment. Dexamethasone can augment the effect of 5-HT3 receptor antagonists like . It is also given in small amounts (usually 5-6 tablets) before and/or after some forms of , such as the extraction of the , an operation which often leaves the patient with puffy, swollen cheeks. conditions, e.g., . It is also given to patients undergoing , to counteract certain of their antitumor treatment. Dexamethasone can augment the effect of 5-HT3 receptor antagonists like . It is also given in small amounts (usually 5-6 tablets) before and/or after some forms of , such as the extraction of the , an operation which often leaves the patient with puffy, swollen cheeks. and conditions, e.g., . It is also given to patients undergoing , to counteract certain of their antitumor treatment. Dexamethasone can augment the effect of 5-HT3 receptor antagonists like . It is also given in small amounts (usually 5-6 tablets) before and/or after some forms of , such as the extraction of the , an operation which often leaves the patient with puffy, swollen cheeks.

In brain tumours (primary or metastatic), dexamethasone is used to counteract the development of edema, which could eventually compress other brain structures. Dexamethasone is also given in cord compression where a tumor is compressing the spinal cord., which could eventually compress other brain structures. Dexamethasone is also given in where a tumor is compressing the spinal cord., which could eventually compress other brain structures. Dexamethasone is also given in where a tumor is compressing the spinal cord. (primary or metastatic), dexamethasone is used to counteract the development of , which could eventually compress other brain structures. Dexamethasone is also given in where a tumor is compressing the spinal cord.

Dexamethasone is also used in certain hematological malignancies, especially in the treatment of multiple myeloma, in which dexamethasone is given alone or together with thalidomide (thal-dex) or a combination of adriamycin and vincristine (VAD). It is injected into the heel when treating plantar fasciitis, sometimes in conjunction with acetonide., in which dexamethasone is given alone or together with (thal-dex) or a combination of and (VAD). It is injected into the heel when treating , sometimes in conjunction with ., in which dexamethasone is given alone or together with (thal-dex) or a combination of and (VAD). It is injected into the heel when treating , sometimes in conjunction with ., especially in the treatment of , in which dexamethasone is given alone or together with (thal-dex) or a combination of and (VAD). It is injected into the heel when treating , sometimes in conjunction with .

It is useful to counteract allergic shock, if given in high doses. It is present in certain eye drops and as a nasal spray (Dexacort®). (Dexacort®). (Dexacort®). and as a (Dexacort®).

Dexamethasone can be used in the context of congenital adrenal hyperplasia, to prevent virilisation of a female fetus. If one or both parents are carriers of mutations to the CYP21A gene, the mother may start dexamethasone treatment within 7 weeks of conception. At the 12th week, a chorionic villus sample will determine whether the fetus is male (in which case the dexamethasone is stopped) or female. Subsequent DNA analysis can then reveal whether the female fetus is a carrier of the mutation, in which case dexamethasone treatment must continue until birth. The side-effects for the mother can be severe and the long-term impact on the child is not clear. of a female fetus. If one or both parents are carriers of mutations to the CYP21A gene, the mother may start dexamethasone treatment within 7 weeks of . At the 12th week, a will determine whether the fetus is male (in which case the dexamethasone is stopped) or female. Subsequent DNA analysis can then reveal whether the female fetus is a carrier of the mutation, in which case dexamethasone treatment must continue until birth. The side-effects for the mother can be severe and the long-term impact on the child is not clear. of a female fetus. If one or both parents are carriers of mutations to the CYP21A gene, the mother may start dexamethasone treatment within 7 weeks of . At the 12th week, a will determine whether the fetus is male (in which case the dexamethasone is stopped) or female. Subsequent DNA analysis can then reveal whether the female fetus is a carrier of the mutation, in which case dexamethasone treatment must continue until birth. The side-effects for the mother can be severe and the long-term impact on the child is not clear., to prevent of a female fetus. If one or both parents are carriers of mutations to the CYP21A gene, the mother may start dexamethasone treatment within 7 weeks of . At the 12th week, a will determine whether the fetus is male (in which case the dexamethasone is stopped) or female. Subsequent DNA analysis can then reveal whether the female fetus is a carrier of the mutation, in which case dexamethasone treatment must continue until birth. The side-effects for the mother can be severe and the long-term impact on the child is not clear.

Dexamethasone is used in the treatment of High Altitude Pulmonary Edema.